Mutation of the adenomatous polyposis coli
Introduction
Many oncogenic defects in human tumours target signal transduction pathways resulting in pathological changes in the activity of transcription factors. These changes can be targeted by DNA viruses containing promoters regulated by the defective pathway. Tumour-specific promoters have been used to regulate the expression of suicide genes, proapoptotic genes and essential viral genes. The therapeutic efficacy of non-replicating viruses expressing suicide genes is limited by the inability clinically to infect a large fraction of tumour cells with injected viruses. Expression of essential viral genes from tumour-specific promoters results in tumour-specific viral replication. [1] [2] [3] [4] In principle, viruses of this type can replicate and spread throughout the tumour mass until all of the tumour cells are killed. Replicating adenoviruses with defects in early genes which can be complemented by p53 and Rb defects in tumour cells have also been described. [5] [6] [7] [8] In practice, only a few cycles of reinfection can occur before the immune system halts the infection. 9 Even a single cycle of infection should lead to a massive local increase in virus concentration within the tumour, making it possible to achieve the same level of infection of tumour cells after injecting much smaller amounts of replicating than non-replicating viruses. Since the toxicity of adenoviruses is closely linked to the amount of virus injected, the risk of immediate life- threatening reactions is potentially much lower with replicating viruses. 10 Recently, our group described adenoviruses that replicate in response to activation of the wnt signalling pathway. 11 The rationale for the development of these viruses was that wnt signalling is pathologically activated in virtually all colon tumours 12 and this leads to transcription from promoters containing Tcf binding sites. 13 The constitutive activation of the wnt pathway is caused by mutations in the APC, axin and ␤-catenin genes that abrogate GSK-3␤ phosphorylation of ␤-catenin and its subsequent degradation by the proteasome. 12 Cytoplasmic ␤-catenin enters the nucleus, where it can associate with members of the Tcf/Lef family of transcription factors and activate transcription of wnt target genes, such as c-myc, cyclin D1, Tcf1 and matrilysin. [14] [15] [16] [17] Other groups have used Tcf promoters to regulate the expression of suicide genes. 18, 19 We placed Tcf binding sites in the adenovirus E2 promoter, which regulates expression of the viral replication genes, because mutations elsewhere in the virus or cell cannot bypass the absolute requirement for E2 gene products in viral replication. In order to achieve tight regulation of E2 transcription, the adjacent E3 enhancer was mutated. Tcf sites were also placed in the E1B promoter, although the level of regulation achieved did not affect viral replication in vitro. These 'Tcf' viruses showed a 50-to 100-fold decrease in replication in nonpermissive cell lines, whereas their activity was comparable to wild-type Ad5 in many, but not all, colon cancer cell lines. 11 The remaining colon cell lines were semipermissive for the Tcf viruses.
We have tested two different approaches to improve Table 1 our existing Tcf viruses and to render them active in a broader range of colon cell lines: mutation of the p300 binding site in E1A, and insertion of Tcf sites in the E1A promoter. Mutation of the p300 binding site in E1A partially relieved E1A-mediated repression of Tcf-dependent transcription, but in the context of the virus this mutation did not lead to increased transcription from the Tcf-E2 promoter and actually reduced the activity of the virus. Similar attenuation by mutation of the aminoterminus of E1A has been reported by the Onyx group. 5 Mutation of all early promoters resulted in highly selective viruses. The new virus containing only the Tcf changes in the E1A and E4 promoters (vCF11) was selective for cells with active wnt signalling and active in most of the colon cancer cells studied.
Results

E1A promoter mutations
The wild-type E1A enhancer contains two types of regulatory element, termed I and II, 20 which overlap the packGene Therapy aging signal (Figure 1a ). In addition to these elements, there are transcription factor binding sites in the inverted terminal repeat (ITR) and close to the E1A TATA box.
To produce a tightly regulated E1A promoter responding only to wnt signals, half of the ITR, the E1A enhancer and the packaging signal were deleted and replaced with four Tcf binding sites. The resulting E1A promoter contains four Tcf sites and a TATA box (Figure 1a ). To maintain the symmetry of the terminal repeats and preserve the ability of the two ITRs to anneal during viral DNA replication, three Tcf sites were inserted in the right ITR. The packaging signal was also inserted at the right end of the genome to permit proper encapsidation of viral DNA. The changes in the ITR do not affect the minimal replication origin. 21 Adenoviral genomic DNA was mutagenised in yeast and converted to virus in C7 cells 22 expressing a stable ␤-catenin mutant. Primary virus stocks were plaque purified and expanded on SW480 cells. The E1A/E4 mutant viruses grew readily on SW480 cells, indicating that the ITR mutagenesis and exchange of the packaging signal are compatible with the pro- duction of viable virus. The structure of the viruses used in this study is summarised in Table 1 and shown schematically in Figure 1b .
Tcf-E1A promoter viruses
To determine whether the Tcf-E1A promoter responds to activation of the wnt pathway, cMM1 cells were infected with vCF11, the virus with only the E1A/E4 promoter changes. cMM1 cells are a clone of H1299 lung cancer cells expressing ⌬N-␤-catenin from a tetracycline-regulated promoter. Wnt signalling was activated by removal of tetracycline from the medium (Figure 2 , lanes 5-8, ⌬N-␤-catenin). This had no effect on E1A expression by wildtype Ad5, but induced expression of E1A by vCF11 ( Figure 2 , compare lanes 3 and 7, E1A). Since DBP is expressed from the normal E2 promoter in vCF11, the DBP level should rise following activation of wnt signalling, because the normal E2 promoter is activated by E1A. The promoter was weakly active in the absence of E1A in H1299 cells, and showed a moderate and reproducible increase in activity following induction of ⌬N-␤-catenin expression ( Figure 2 , lanes 3 and 7, DBP). We conclude that the mutant E1A promoter responds to activation of the wnt pathway, and this feeds through to an effect on expression of viral replication proteins. The effect of the Tcf-E1A/E4 promoter substitutions was then tested on a panel of colon cell lines with active wnt signalling: SW480, ISREC-01 and HT29 have mutant APC; Hct116 has mutant ␤-catenin; and Co115 has microsatellite instability, but the defect in wnt signalling has not been defined. 23 Three control cell lines with inactive wnt signalling were tested: H1299, HeLa and low passage normal human small airway epithelial cells (SAEC). E1A was detectable by Western blotting 24 h after vCF11 infection of all of the colon cell lines, but not H1299, HeLa or SAEC (Figure 3, lane 3, E1A ). Relative to wild-type Ad5, the level of E1A expression was higher in SW480 and ISREC-01, the same in Co115 and lower in HT29 and Hct116 (Figure 3 , compare lanes 2 and 3, E1A). The hierarchy of responsiveness of the Tcf-E1A promoter in the different cell lines was thus the same as with the Tcf-E2 viruses, 11 but the level of expression relative to the normal promoter was higher for E1A than E2. Since the E1B and E2 enhancers are wild-type in vCF11, these transcription units should be inducible by E1A. The E4 promoter in vCF11 is potentially able to respond to both E1A and Tcf. To test this, the blots were probed for E1B 55k, DBP and E4orf6. Consistent with the E1A results, all three proteins were expressed normally in SW480, ISREC-01 and Co115, and undetectable in HeLa and SAEC ( Figure 3, compare lanes 2 and 3) . Despite the absence of E1A expression, all three proteins were expressed weakly in H1299 cells, suggesting that these cells contain an endogenous activity which can substitute for E1A. Compared with wild-type infections, the level of E1B 55k, DBP and E4orf6 was slightly reduced in HT29 and more substantially reduced in Hct116 cells infected with vCF11 ( Figure 3 , compare lanes 2 and 3).
Viruses with Tcf sites in multiple early promoters
To test the effect of regulating E1A expression in the context of the previous generation of Tcf viruses, cells were infected with vMB31 (B23Ј) and vCF22 (AB23Ј4; Figure  3 , compare lanes 5 and 6). E1A and E4orf6 expression were well preserved in SW480, ISREC-01 and Co115 infected with vCF22, but DBP expression was maintained only in SW480 and ISREC-01, and even there it was slightly lower with vCF22 than wild-type Ad5 (Figure 3 , compare lanes 2 and 6, DBP). In the remaining cell lines, DBP expression was undetectable with vCF22. Insertion of Tcf sites in the E1A, E1B, E2 and E4 promoters in vCF22 abolished the E1A-independent expression of E1B 55K, DBP and E4orf6 seen in H1299 infected with vCF11 ( Figure 3 , compare lanes 3 and 6, H1299). We conclude that insertion of Tcf sites into multiple early promoters produces an extremely selective virus, but one with reduced activity in some colon cell lines.
Inhibition of Tcf-dependent transcription by E1A
The defect in early gene expression from the Tcf viruses in the semi-permissive cell lines is not restricted to a single promoter. Instead, there appears to be a general Gene Therapy defect in activation of viral Tcf promoters. This can be partly explained by generally weaker Tcf activity. The reason for this is unclear, but it does not reflect a lack of wnt pathway activation per se, since the semi-permissive cell lines contain mutations in either APC or ␤-catenin, and the Tcf-E2 transcriptional activity measured by luciferase assay is not increased by transfection of exogenous ⌬N-␤-catenin ( Figure 4 ).
An alternative explanation for the semi-permissivity of some cell lines is that E1A could be inhibiting the viral Tcf promoters, for example by sequestering p300, which is a coactivator of Tcf-dependent transcription. 24, 25 To determine whether E1A inhibits the viral Tcf promoters, we performed transcription assays using the Tcf-E1A and Tcf-E2 promoters coupled to the luciferase gene. In SW480, the Tcf-E2 promoter was more active than the wild-type E2 promoter in the absence of E1A (Figure 5b , lanes 1 and 6), and gave almost exactly wild-type activity in the presence of E1A ( Figure 5b , lanes 2 and 7). This convergence was due to increased wild-type E2 promoter activity and decreased Tcf-E2 promoter activity in the presence of E1A. Mutation of the E3 promoter is required to produce a tightly regulated Tcf-E2 promoter, because the E3 promoter is adjacent to the E2 promoter.
11 E3 mutation reduced the activity of the E2 promoter slightly in SW480 cells transfected with E1A, but the activity was still close to that seen with the wild-type promoter ( Figure 5b, lanes 2 and 12) . The high activity of the Tcf-E2 promoter in SW480 probably explains why this cell line is permissive for all of the Tcf viruses. In contrast, the level of Tcf-E2 activity in the presence of E1A was substantially below the wild-type level in Co115 and Hct116 cells (Figure 5c and d, lanes 2, 7 and 12) .
To determine the mechanism of inhibition, we tested different E1A mutants (Figure 5a) . Mutation of the Rb binding site in E1A impaired transactivation of the wildtype E2 promoter in SW480 and Co115 (Figure 5b and c, lane 3), but not in Hct116 cells (Figure 5d, lane 3) , whereas mutation of the p300 or p400 binding sites had little effect on transactivation of the wild-type promoter by E1A in all three cell lines (Figure 5b , c and d, lanes 4 and 5). Reduced transactivation by an E1A mutant unable to bind Rb is expected, given the presence of E2F sites in the E2 promoter. The Tcf sites replace the normal enhancer in the Tcf-E2 promoter. 11 In all three cell lines the Rb and p400 binding site mutations did not relieve inhibition of the Tcf promoters by E1A (Figure 5b , c and d, lanes 8, 10, 13 and 15). The only mutation to have an effect was the p300 binding site mutation (E1A ⌬2-11, labelled ⌬p300N), and in SW480 and Co115 the maximum recovery never exceeded 50% of the lost activity ( Figure  5b and c, lanes 9 and 14). Mutation of E1A amino acid 2 to glycine (R2G), which also blocks p300 binding, had the same effect (data not shown). In Hct116, the ⌬p300N mutation completely restored activity of the Tcf-E2 pro-275 moter (Figure 5d, lane 9) . Interestingly, we have noticed by Western blotting that p300 is mutant in this cell line (the protein has a mobility on SDS-PAGE of approximately 240 kDa, data not shown). The effect of the mutation in E1A is therefore surprising in this cell line, but could reflect E1A binding to CBP or to the residual p300 fragment.
Analysis of additional E1A mutants
To explore possible explanations for the incomplete recovery of activity after mutation of the p300 binding site in E1A, additional luciferase assays were performed in H1299 cells ( Figure 6 ). The Tcf-E2 promoter was activated 10-fold by ⌬N-␤-catenin (Figure 6a , compare lanes 1 and 2), and this was inhibited by E1A (Figure 6a, lane  3) . p300 binds to two sites in E1A and mutation of either site partially relieved the inhibition of Tcf-dependent transcription (E1A ⌬p300N and ⌬p300C, Figure 6a , lanes 4 and 5). The C-terminal p300 binding site lies within the conserved domain 1 (CR1), but deletion of the entire domain did not restore activity (Figure 6a , lane 6). This suggests that there may be a positively acting factor which binds somewhere in CR1. To determine whether the E1A ⌬p300N mutation only partially restored activity because it did not completely block p300 binding, we cotransfected increasing amounts of p300 with E1A ( Figure 6b ). Exogenous p300 reversed the inhibition of promoter activity to the same extent as mutation of the p300 binding site (Figure 6b, lanes 4 and 7) , and the effects of the ⌬p300N mutation and p300 transfection were not additive ( Figure 6b, lane 8) . Large amounts of exogenous p300 reduced promoter activity (Figure 6b , lanes 5, 6, 9 and 10), suggesting that a cofactor was being titrated. P/CAF is a candidate for this cofactor because it is a histone acetyltransferase (HAT) that binds to p300, and the coactivation of Tcf by p300 does not require intrinsic p300 HAT activity. 24 Since E1A inhibits P/CAF, 26 we tested whether mutation of the P/CAF binding domain in E1A relieved inhibition of Tcf activity by E1A, but saw no effect (Figure 6a, lane 7) . P/CAF was not limiting because cotransfection of P/CAF and wildtype or ⌬P/CAF mutant E1A also failed to restore activity (Figure 6c, lanes 4 and 9) . To test whether p300 and P/CAF act together, an E1A gene with mutations in the binding sites for both HATs was constructed (labelled ⌬⌬ in Figure 6 ), but this mutant also failed to relieve the repressive effect of E1A (Figure 6a, lane 8) , as did cotransfection of P/CAF and E1A mutant in the p300 binding site (Figure 6c, lane 6) , or cotransfection of p300 and E1A mutant in the P/CAF binding site (Figure 6c, lane 8) .
As in colon cells ( Figure 5 ), mutation of the Rb binding site in E1A had no effect on repression of Tcf-dependent transcription (Figure 6a, lane 9 ). CtBP and TIP49 have both been implicated in transcription activation by Tcf, 27 ,28 but neither mutations in E1A which abolish CtBP binding (⌬CtBP, ⌬C52; Figure 6a , lanes 10 and 11) nor transfection of wild-type or dominant negative TIP49 (Figure 6c, lanes 10 and 11) could overcome the repressive effect of E1A. In conclusion, the E1A mapping studies showed that mutation of the p300 binding domain could restore about half of the Tcf activity lost upon E1A expression, but the remaining repressive effect could not be mapped to a known domain in E1A.
Gene Therapy 
E1A ⌬p300N mutant Tcf viruses
To test whether deletion of the p300 binding site in E1A would increase the activity of the Tcf promoters in the context of the virus, the ⌬p300N mutation was introduced into the Tcf-E1A, Tcf-E1B, Tcf-E2 and Tcf-E4 viruses (Table 1 and Figure 1b) . For the Tcf-E1A promoter, inhibition of p300 by E1A should inhibit expression of E1A itself. This was tested by infecting the cMM1 cell line with vCF11 and vCF42, the ⌬p300N derivative of vCF11, in the presence and absence of tetracycline. Consistent with there being negative feedback by E1A on its own expression, the level of E1A after activation of wnt signalling was higher with vCF42 than vCF11 (Figure 2, compare lanes 7 and 8, E1A ). Despite the increase in E1A expression, there was no difference in DBP expression, possibly because the ⌬p300N mutant is defective in some other function required for activation of the wild-type E2 promoter (Figure 2, compare lanes 7  and 8, DBP) . The multiply-mutated viruses were then tested on a panel of cell lines (Figure 3) . The effect of the ⌬p300N mutation can best be appreciated by comparing matched pairs of viruses: vCF11 versus vCF42 (Figure 3,  lanes 3 and 4) ; vMB19 versus vCF81 (Figure 3, lanes 9 and  8) ; and vCF22 versus vCF62 (Figure 3, lanes 6 and 7) . In each case the latter is derived from the former by deletion of the p300 binding site in E1A (the only exception is that the E3 promoter ATF site is present in vCF22, but absent in vCF62). In almost every case the ⌬p300N mutation actually reduced the level of expression of E1B 55K, DBP and E4orf6. The only promoter whose activity was reasonably well maintained was the Tcf-E1A promoter ( Figure 3, lanes 4 and 7, E1A ). The wild-type E1A promoter was also little affected by the E1A ⌬p300N mutation ( Figure 3, lane 8, E1A ). After infection with the most comprehensively mutated virus (vCF62), viral proteins were undetectable in the control cell lines ( Figure  3 , lane 7, H1299, HeLa and SAEC) and barely detectable in the semi-permissive colon cell lines (Co115, HT29 and Hct116). The expression of DBP and E4orf6 was also decreased in the permissive cell lines (SW480 and ISREC-01), when multiple promoter changes were combined with the E1A ⌬p300N mutation. In the absence of this mutation, the virus with multiple promoter changes (vCF22) showed wild-type expression of E1A, E1B55k, DBP and E4orf6 in the permissive cell lines (SW480 and ISREC-01). The E1A ⌬p300N mutation did not increase E1B 55K or DBP expression in any of the viruses with Tcf-E1B and Tcf-E2 promoters (Figure 3 , compare lanes 6 versus 7, and 9 versus 8). We conclude that in the context of the virus, the E1A ⌬p300N mutation does not rescue the defect in Tcf promoter activity in the semi-permissive cell lines.
Since this result was unexpected, we also tested the new viruses in cytopathic effect and burst assays. In the most permissive colon cell line, SW480, both vCF11 and vMB19 were at least 10-fold more active than wild-type Ad5 in CPE assays (Figure 7a , compare lane 1 with lanes 2 and 6). For these viruses, the corresponding p300 mutant viruses were about 10-fold less active (Figure 7a , compare lanes 2 versus 3, and 6 versus 7). Only for the virus with Tcf sites in the E1A, E1B, E2 and E4 promoters was the p300 mutant virus as active as the parent ( Figure  7a , compare lanes 4 versus 5), but these viruses were 100-fold less active than the virus with only the Tcf-E1A/E4 changes (vCF11, Figure 7a , lane 2). vCF11 showed wildtype activity on Co115 (Figure 7b, compare lanes 1 versus  2) . This is 10-fold better than the previous best virus, vMB19 (Figure 7b, lane 6) . In Hct116, the situation was reversed: vMB19 was slightly better than vCF11, but wild-type was better than either Tcf virus (Figure 7c,  lanes, 1, 2 and 6 ). In Co115, all of the p300 mutant viruses were 10-fold less active than the corresponding viruses with wild-type E1A (Figure 7b , compare lanes 2 versus 3, 4 versus 5, and 6 versus 7). All of the Tcf viruses were substantially less active than wild-type Ad5 on HeLa cells, which lack Tcf activity (Figure 7d) . The most engineered viruses failed to produce plaques on HeLa even after infection with 100 p.f.u./cell (Figure 7d, lanes 4 and  5) . The effect of mutation of the p300 binding site in E1A was less obvious than on permissive cells. Overall, the best virus was vCF11, which was 10-fold less active than vMB19 and 1000-fold less active than wild-type Ad5 on Hela cells (Figure 7d, lanes 1, 2 and 6 ). Since vCF11 is 10-fold more active than wild-type Ad5 on SW480, its overall selectivity for the most permissive colon cells is 10 000-fold relative to wild-type Ad5.
In burst assays, the effect of the p300 binding site mutation was specific to the virus and the cell line. In SW480, the mutation reduced burst size 50-fold in the 'A4' backbone ( Figure 8, compare lanes 2 and 3) , but had almost no effect in the 'B23' backbone ( Figure 8 , compare lanes 4 and 5). This difference may be due to the fact that the E2 promoter requires E1A function in vCF42, where the wild-type E2 enhancer is activated by ATF and E2F, but not in vCF81, where the E2 enhancer is replaced by Tcf sites. The virus with Tcf sites in all the early promoters and the ⌬p300 mutation in E1A (vCF62) was 100-fold less active than wild-type in SW480. vCF62 was almost as active as vCF42 ( 
Discussion
The goal of this study was to create adenoviruses which replicate efficiently in a wide range of colon cancer cells, but not in normal cells. We tested viruses with Tcf sites in multiple viral early promoters and mutation of the p300 binding site in E1A. Compared with the previous generation of Tcf viruses, 11 vCF11 is less toxic to cells lacking wnt activity and has broader activity in a panel of colon cancer cell lines in cytopathic effect assays. It has Tcf sites in both ITRs, but only E1A transcription is tightly regulated by wnt signalling. This is partly explained by the fact that the Tcf sites are adjacent to the TATA box in the Tcf-E1A promoter, but several hundred base pairs upstream of the E4 TATA box. To create an E1A promoter with the minimum possibility of interference from extraneous signals, all of the normal regulatory elements were deleted in vCF11. This contrasts with the approach used to produce prostate, hepatocellular cancer and breast cancer targeting viruses, which retain the complete E1A enhancer, but place exogenous promoters between it and the E1A start site. 1, 3, 4 To remove the E1A enhancer in vCF11, it was necessary to transfer the viral packaging signal to the right ITR. In addition, half of the ITR was replaced by Tcf sites. This construction dictated the position of the Tcf sites relative to the E4 start site. The endogenous E4 control elements were retained in vCF11 because they confer repression of E4 transcription in normal cells. 29 The mutant E4 promoter thus contains the part of the E1A enhancer contained in the packaging signal, which could activate the promoter, flanked by Tcf
Figure 7 Cytopathic effect assays in different cell lines infected with 10-fold dilutions of wild-type Ad5 and Tcf viruses. (a) SW480 cells were infected at a starting multiplicity of 10 p.f.u./cell and stained 6 days after infection. (b) Co115 and (c) Hct116 were infected at a starting multiplicity of 100 p.f.u./cell and stained 7 days after infection. (d) HeLa were infected at a starting multiplicity of 100 p.f.u./cell and stained 8 days after infection.
and E4F sites, which should repress the promoter in normal cells. The net result of these changes is reduced E4 transcription measured by luciferase assay, regardless of cell type (C Volorio and C Fuerer, unpublished data).
Replication of the previous generation of viruses is restricted to cells with activated wnt signalling by the Tcf sites in the E2 promoter. 11 vCF62 and vCF22, which have Tcf sites in multiple early promoters, were even more severely attenuated in cells lacking wnt activity. In cytopathic effect assays in HeLa cells, they were at least 10 4 -fold less active than wild-type virus, and in burst assays in HeLa and SAEC, vCF62 was 10 5 -to 10 7 -fold less active than wild-type virus. The reduced activity of these viruses in permissive cells might be due to deletion of element II in the E1A enhancer, which was previously reported to activate transcription of all of the early promoters in cis. 20 Comparison of different viruses shows
Gene Therapy that the Tcf-E1A and Tcf-E2 promoters display the same hierarchy of activity in a panel of colon cell lines, but relative to the corresponding wild-type promoters, the Tcf-E1A promoter is more active than the Tcf-E2 promoter. This probably explains why vCF11 is able to replicate better than vMB19 in Co115 cells. Notwithstanding minor differences between different Tcf promoters in the semi-permissive cell lines, there is a clear overall trend for Tcf promoters to be less active in some colon cell lines. Other groups have noted similar differences in wnt activity in colon cancer cell lines. 18, 19 All of the cell lines tested (except Co115, where the defect is not known) and virtually all colon tumours possess APC or ␤-catenin mutations resulting in activation of the wnt pathway. This indicates that wnt activation is a critical step in colon cancer tumorigenesis. It is possible that the modest Tcf activity seen in some colon cell lines reflects a loss of activity during later tumour development or in vitro culture. In this case, there is no need to improve the existing Tcf viruses. The wnt pathway is regulated at many levels, but the fact that exogenous mutant ␤-catenin does not increase Tcf activity allows us to rule out many upstream problems. Possible differences which could explain the reduced Tcf activity in some cell lines include increased expression of corepressors like groucho and CtBP, decreased expression of coactivators like p300 and CBP, acetylation or phosphorylation of Tcf4 preventing ␤-catenin binding or DNA binding, and increased activity of the ⌬N-Tcf1 negative feedback loop. 16, 30 Luciferase reporter assays showed a systematic inhibition of Tcf-dependent transcription by E1A. Mutagenesis of E1A indicated that this effect was partly due to inhibition of p300 by E1A, consistent with reports that p300 is a coactivator for ␤-catenin. 24, 31 Coexpression of p300 together with E1A had the same effect on Tcfdependent transcription as deletion of the p300 binding site in E1A, indicating that the remaining repression was unlikely to be due to inhibition of p300. The residual repressive effect of E1A could not be mapped to any known domain and merits further study. The negative results obtained with the ⌬CR1 mutant are surprising because deletion of the CR1 p300-binding subdomain alone did partially restore Tcf-dependent transcription. This could conceivably be explained by an artefactual elevation of transcription of the renilla luciferase control by ⌬CR1 E1A, but a more likely explanation is that another function of E1A is impaired by deletion of the entire CR1 domain.
The inhibition of Tcf-dependent transcription by E1A was greatest in the semi-permissive cell lines like Co115, resulting in very low luciferase activity because the starting level of Tcf activity was also lower in these cells. Hence, we expected to see a substantial effect of the ⌬2-11 E1A mutation in the context of the viruses. In practice, the mutation produced no increase in expression from the Tcf-E2 promoter in colon cell lines and reduced the activity of the virus in cytopathic effect assays. There was a small, but reproducible increase in E1A protein level in cMM1 cells expressing mutant ␤-catenin infected with A⌬4 virus (vCF42) compared with A4 virus (vCF11), which would be consistent with decreased negative feedback of E1A on its own expression through relief of p300 inhibition, but the increase in E1A level could be due to protein stabilisation. Consistent with the latter explanation, we have observed stabilisation of lower mobility E1A isoforms in SW480 infected with ⌬p300N virus (data not shown). The mutation had complex and inconsistent effects in burst assays: it appeared to reduce burst size in permissive cells, when the E2 promoter was driven by E1A (ie wild-type), but increase burst size in some nonpermissive cells, when the E2 promoter was driven by Tcf. A general explanation is that any gain in Tcf activity due to the E1A mutation was offset by a loss of other E1A activities. Since we only tested 12S E1A, it is possible that these functions map to the other E1A isoforms expressed during viral infection. In addition, there are some basal promoter activities regulated by E1A which may be abrogated by the ⌬2-11 mutation. [32] [33] [34] [35] In conclusion, we have shown that adenovirus replication can be regulated by insertion of Tcf sites into the E1A or E2 promoters. Mutation of the p300 binding site in E1A did not increase transcription from Tcf promoters in the context of the virus. Since the E1A ⌬2-11 mutation consistently reduced virus activity in cytopathic effect assays, it would be better to retain this domain in therapeutic viruses.
Materials and methods
Adenovirus mutagenesis
An Ad5 E1A fragment (nucleotides nt 1 to 952) was amplified by PCR from ATCC VR5 adenovirus 5 genomic DNA with primers CGGAATTCAAGCTTAATTAACAT CATCAATAATATACC (G76) and GGGTGGAAAGCC AGCCTCGTG (oCF1), cut with PacI, and cloned into the BamHI/PacI sites in pMB1 to give pCF4. pMB1 contains the left end of Ad5 cloned into the EcoRI/SmaI sites of pFL39. 11, 36 The endogenous adenoviral sequence from the middle of the ITR to the E1A TATA box was replaced with four Tcf binding sites by inverse PCR with primers tccAGATCAAAGGGattaAGATCAAAGGGccaccacctcattat (oCF3) and tCCCTTTGATCTccaaCCCTTTGATCTagt cctatttatacccggtga (oCF4) to give pCF25 (the Tcf sites in the primers are shown in capitals). The final sequence of the mutant ITR and E1A promoter is catcatcaataatat accttattttggattgaagccaatatgataatgaggTggtggCCCTTTGAT CTTAATCCCTTTGATCTGGATCCCTTTGATCTCCAAC CCTTTGATCTAGTCCtatttata, where the wt Ad5 sequence is in lowercase and the E1A TATA box is underlined. A G to T mutation was introduced just before the first Tcf binding site to mutate the Sp1 binding site. 37 The Ad5 E4 fragment (nt 35369 to 35938) was amplified by PCR from VR5 DNA with primers G76 and ACCCGCAGGCGTAGAGACAAC (oCF2), cut with PacI and cloned into the BamHI/PacI sites in pMB1 to give pCF6. To compensate for the mutations introduced in the left ITR, three Tcf binding sites were introduced, and the endogenous sequence (nt 35805 to 35887) was simultaneously deleted by inverse PCR with primers oCF3 and tCCCTTTGATCTccactagtgtgaattgtagttttcttaaaatg (oCF5) to give pCF16 (the Tcf site is shown in capitals and the SpeI site is underlined). The packaging signal was amplified by PCR from pCF6 with primers GAACTAGTAG TAAATTTGGGCGTAACC (oCF6) and ACGCTAGC AAAACACCTGGGCGAGT (oCF7), cut with SpeI/NheI and cloned into the SpeI site in pCF6 to give pCF34. The packaging signal has the same end-to-centre orientation as at the left end of the adenoviral genome.
The ⌬2-11 mutation was introduced in two steps. First, plasmids pCF4 (wild-type E1A promoter) and pCF25 (Tcf-E1A mutant) were cut by SnaBI/SphI following by self ligation to give pRDI-283 and pRDI-284, respectively. Second, the 2-11 region in pRDI-283 and pRDI-284 was deleted by inverse PCR with primers CATTTTCAGTCCC GGTGTCG (oCF8) and ACCGAAGAAATGGCCGCCAG (oCF9) to give pCF61 and pCF56, respectively.
The YAC/BAC vector pMB19 38 was cut with PacI followed by self ligation to give pCF1, a YAC/BAC vector harbouring a unique PacI site.
In order to produce the gap repair vectors, combinations of left and right adenoviral ends were first assembled and then transferred to the YAC/BAC vector itself. During the first step, pCF34 was cut with EcoRI/SalI and cloned into the Pst/SalI sites of pCF25 to give pRDI-285. Similarly, pCF56 was cut with HindIII/SalI and cloned into the PstI/SalI sites of pCF34 to give pCF46. Finally pCF61 was cut with HindIII/SalI and cloned into the PstI/SalI sites of pCF16 to give pCF52. pRDI-285, pCF46 and pCF52 all contain a cassette with the left and right ends of the genome separated by a unique SalI site. These cassettes were isolated by PacI digestion and cloned into the PacI site of pCF1 to give pCF78, pCF79 and pCF81, respectively. pCF78 has mutant E1A and E4 promoters, pCF79 has mutant E1A and E4 promoters plus the ⌬2-11 mutation, and pCF81 has wild-type E1A and E4 promoters plus the ⌬2-11 mutation.
vCF11 and vCF22 were constructed by gap repair 38 of pCF78 with VR5 (ATCC) and vMB31 11 DNA, respectively. vCF42 and vCF62 were constructed by gap repair of pCF79 with VR5 and vMB19 DNA, 11 respectively. vCF81 was constructed by gap repair of pCF81 with vMB31 DNA. The viral DNA was cut with ClaI before gap repair to target the recombination event to a site internal to the mutations at the left end of the genome.
Viral genomic DNA was converted into virus by transfection of PacI digested YAC/BAC DNA into cR1 cells. The viruses were then plaque purified on SW480 cells, expanded on SW480, purified by CsCl banding, buffer exchanged using NAP25 columns into 1 M NaCl, 100 mM Tris-HCl pH 8.0, 10% glycerol and stored frozen at Ϫ70°C. The identity of each batch was checked by restriction digestion and automated fluorescent sequencing on a Licor (Lincoln, NE, USA) 4200L sequencer in the E1A (nt 1-1050), E1B (nt 1300-2300), E2/E3 (nt 26700-27950) and E4 (nt 35250-35938) regions using primers IR213 (E1A antisense: CAGGTCCTCATATAGCAAAGC), IR190 (E1B sense: TGTCTGAACCTGAGCCTGAG), IR110 (E2/E3 sense: CATCTCTACAGCCCATAC), IF171 (E2/E3 antisense: AGTTGCTCTGCCTCTCCAC) and IR215 (E4 sense: CGTGATTAAAAAGCACCACC). Apart from the desired mutations, no differences were found between the sequence of VR5 and the Tcf viruses. Particle counts were based on the OD 260 of virus in 0.1% SDS using the formula 1 OD 260 = 10 12 particles/ml.
Gene Therapy E1A, p300, P/CAF, Tip49 and ␤-catenin plasmids Wild-type 12S E1A (pCF9) and E1A mutants ⌬pRb (124A,135A), ⌬p300N (⌬2-11), ⌬p300C (⌬64-68), ⌬p400 (⌬26-35), ⌬P/CAF (E55), ⌬CtBP (LDLA4), and ⌬C52 were described by Alevizopoulos et al 39, 40 and Reid et al. 26 All the mutants were provided in a pcDNA3 backbone (Invitrogen, Carlsbad, CA, USA) except the ⌬p300N and ⌬p300C mutants that were isolated with BamHI/EcoRI and cloned into the BamHI/EcoRI sites of pcDNA3. The ⌬CR1 mutant (⌬38-68) was made by inverse PCR of pCF9 with primers TCTGTAATGTTGGCGGTGCAGGAAG (oCF10) and ATGGCTAGGAGGTGGAAGAT (oCF12) to give pCF45. The ⌬⌬ p300-P/CAF double mutant was constructed by three-way ligation of BstXI fragments from the single mutants. The E1A mutants are shown in Figure 5a . The ⌬N-␤-catenin plasmid was described by van de Wetering et al. 41 The p300 vector contains HAtagged p300 expressed from the CMV promoter. The P/CAF expression vector was described by Blanco et al. 42 The Tip49 and Tip49DN vectors were described by Wood et al. 43 Cell lines ISREC-01, 44 SW480 (ATCC CCL-228) and Co115 23 were supplied by Dr B Sordat (ISREC). HCT116 (CCL-247), HT29 (HTB-38), 293T were supplied by ATCC. HeLa (CCL-2) were supplied by ICRF. H1299 were supplied by Dr C Prives (Columbia University). 45 The cMM1 cell line expressing myc-tagged ⌬N-␤-catenin 41 from the tet-off promoter will be described elsewhere (M Malerba and R Iggo, manuscript in preparation). C7 cells were supplied by Dr J Chamberlain (University of Michigan). 22 To create the cR1 packaging cells, C7 cells were infected with a lentivirus expressing myc-tagged ⌬N-␤-catenin.
11,41 Clonetics small airway epithelial cells (SAEC) and SAGM medium were supplied by Cambrex (East Rutherford, USA). All the other cell lines were grown in DulbeccoЈs modified EagleЈs medium with 10% foetal calf serum (Invitrogen).
Luciferase assays
The E2 reporters were described by Brunori et al. 11 To construct E1A reporters, wild-type and mutant E1A promoters were amplified by PCR from pCF4 and pCF25, respectively, with primers G76 and GTGTCGGA GCGGCTCGGAGG (oCF13), cut with HindIII, and cloned into the NcoI/HindIII sites of pGL3-Basic (Promega, Madison, WI, USA). Cells were seeded at 2.5 × 10 5 cells per 35-mm well 24 h before transfection. 4.5 l of Lipofectamine (Invitrogen) was mixed for 30 min with 100 ng of reporter plasmid, 1 ng of control Renilla luciferase plasmid (Promega) and 500 ng of vectors expressing E1A, P/CAF, p300 or TIP49. pcDNA3 empty vector was added to equalise the total amount of DNA. In Figure 6b , 0.5, 1 and 2 g of p300 vector were used. Cells were harvested 48 h after transfection and dual luciferase reporter assays performed according to the manufacturerЈs instructions (Promega) using a Biocounter (Lumac, Landgraaf, The Netherlands). Each value is the mean of one to nine independent experiments done in triplicate, and transfection efficiency is normalised to the activity of the Renilla control.
Western blotting
Cells were infected with 1000 viral particles per cell. Two hours after infection, the medium was replaced. Cells were harvested 24 h later in SDS-PAGE sample buffer. E1A, E1B55K, DBP and E4orf6 were detected with the M73 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), 2A6, 46 B6 47 and RSA3 48 monoclonal antibodies, respectively. Myc-tagged ␤-catenin was detected with the 9E10 monoclonal antibody. 49 Cytopathic effect assay Cells in six-well plates were infected with 10-fold log dilutions of virus. Two hours after infection, the medium was replaced. After 6 to 8 days (Figure 7) , the cells were fixed with paraformaldehyde and stained with crystal violet.
Virus replication assay
Cells in six-well plates were infected with 300 viral particles per cell. Two hours after infection, the medium was replaced. Cells were harvested 48 h later and lysed by three cycles of freeze-thawing. The supernatant was tested for virus production by counting plaques formed on SW480 cells after 10 days under 1% Bacto agar in DMEM 10% FCS. Each bar in the Figure represents the mean ± s.d. of triplicate plaque assays.
